A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

NSCLC Clinical Trial

— WUKONG-9  

Official title:

Efficacy and Safety of Sunvozertinib With Anlotinib in EGFR-TKIs Resistant EGFR-sensitive Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC): a Prospective, Single-arm, Phase II Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06182761
• Other study ID #: WUKONG9
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 2024
• Est. completion date: July 2028

Study information

• Verified date: December 2023
• Source: Shanghai Zhongshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 45
• Est. completion date: July 2028
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.

2. Pathologically confirmed non-squamous NSCLC. Locally advanced or metastatic NSCLC

3. EGFR sensitive mutations confirmed by accredited local laboratories, including 19del?L858R and T790M?

4. Intolerant or refuses, or not suitable for systemic chemotherapy.

5. Progressed after EGFR-TKI targeted therapy or are intolerant to standard treatment; if carry T790M mutation, need to be treated with osimertinib or other third-generation EGFR-TKI.

6. World Health Organization performance status of 0 to 1

7. Life expectancy >12 weeks at Day 1.

8. At least 1 lesion to be measured

9. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential, or must have evidence of non-childbearing potential by fulfilling criteria at screening.

10. Male patients must be willing to use barrier contraception

Exclusion Criteria:

1. Any known RET rearrangement, BRAF V600E mutation, NTRK fusion, MET ex14 skip mutation, MET amplification (defined as tissue detection GCN = 5 by NGS)

2. Any concurrent and/or other active malignancy within 2 years

3. Major surgery within 4 weeks of the first dose of IP

4. Any unresolved toxicities from prior therapy.

5. Past medical history of ILD (interstitial lung disease)/pneumonitis, drug-induced ILD/pneumonitis, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD/pneumonitis

6. Any evidence of severe or uncontrolled systemic diseases.

7. Any of the following cardiac criteria:

i) Mean resting QTc >470 msec ii) Any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram iii) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events

8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of Sunvozertinib and Anlotinib

9. Severe allergies to Sunvozertinib and Anlotinib

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC

Intervention

Drug:
• Sunvozertinib combination with Anlotinib
Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily (QD in Day 1-14) ,21 days in one cycle.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Objective response rate (ORR) as assessed by the investigator according to RECIST 1.1 criteria.	initiate from first dose until the date of confirmed response, assessed up to 24 weeks
Secondary	PFS	PFS as assessed by the investigator according to RECIST 1.1	initiate from first dose, every 6 weeks until PD or study close, an average of 1 year
Secondary	OS	initiate from first dose to death from any cause	through study completion, an average of 1.5 years
Secondary	DoR	The period from the first judgment of CR or PR to PD	an average of 1 year
Secondary	AE	TRAE as assessed by the investigator according to CTCAE 5.0	through study completion, an average of 1 year